A Phase 3 interventional study of Teduglutide 0.05mg/kg and Teduglutide 0.025 mg/kg in Short Bowel Syndrome, sponsored by Shire. Completed at 27 sites in 7 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 16 in phase 3, and was the 10th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 0 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2016.
This study's enrollment of 59 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2016, is one of 17 in phase 3, and was the 10th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
Teduglutide is approved for treatment of adults with short bowel syndrome (SBS). The purpose of this study is to evaluate the safety and efficacy of teduglutide in children up to the age of 17 with SBS who are dependent on parenteral support. Subjects may choose whether to receive the study drug or to participate in a standard-of-care arm. All participants who complete the study may be eligible to receive the study drug in a long-term extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Signs of active severe or unstable, clinically significant hepatic impairment during the screening period, as indicated by any of the following laboratory test results :
Alanine aminotransferase (ALT) ≥ 7x ULN
For subjects with Gilbert's disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.
Drug: Teduglutide 0.025 mg/kg
0.05 mg/kg/day of teduglutide for 24 weeks.
Drug: Teduglutide 0.05mg/kg
Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
Other: Standard of Care
Drug page: Teduglutide
0.05 mg/kg
Drug page: Teduglutide
0.025 mg/kg
Observational cohort for the 24-week treatment period and 4 week follow-up.
Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24
Reduction in weight-normalized PN/IV volume was performed using both participant diary and investigator prescribed data. Number of participants who achieved at least a 20% reduction in weight-normalized PN/IV volume between the baseline and week 24/EOT visit were reported.
Time frame: Baseline through Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs that started or worsened on or after the date of first dose for treatment groups and those that started or worsened on or after the baseline visit for standard of care group.
Time frame: From start of study treatment up to 28 weeks
Number of Participants Who Were Completely Weaned Off Parenteral Nutrition Intravenous (PN/IV) Support at Week 24
A participant was considered to have achieved independence from PN/IV support (completely weaned off PN/IV) if the investigator prescribed no PN/IV at EOT and there was no use of PN/IV recorded in the participant diary during the week prior to EOT.
Time frame: Week 24
Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24
Change in PN/IV volume was reported based on the participant diary and the investigator prescribed data.
Time frame: Baseline, Week 24
Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 24
Change in PN/IV caloric intake was reported based on the participant diary and the investigator prescribed data.
Time frame: Baseline, Week 24
Change From Baseline in Plasma Citrulline Levels at Week 24
Plasma citrulline level was reported.
Time frame: Baseline, Week 24
Change From Baseline in Enteral Nutrition Volume at Week 24
Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.
Time frame: Baseline, Week 24
Change From Baseline in Enteral Nutrition Caloric Intake at Week 24
Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.
Time frame: Baseline, Week 24
Change From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 28
Change in PN/IV volume was reported.
Time frame: Week 24, Week 28
Change From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 28
Change in PN/IV caloric intake was reported.
Time frame: Week 24, Week 28
Change From Week 24 in Plasma Citrulline Levels at Week 28
Change in plasma citrulline level was reported.
Time frame: Week 24, Week 28
Change From Week 24 in Enteral Nutrition Volume at Week 28
Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.
Time frame: Week 24, Week 28
Change From Week 24 in Enteral Nutrition Caloric Intake at Week 28
Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.
Time frame: Week 24, Week 28
Change From Baseline in Body Weight Z-score at Week 28
Body weight z-score is a measure of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
Time frame: Baseline, Week 28
Change From Baseline in Body Height Z-score at Week 28
Body height z-score is a measure of relative height adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
Time frame: Baseline, Week 28
Change From Baseline in Head Circumference Z-score at Week 28
Head circumference z-score is a measure of relative head circumference adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Head circumference was collected only for participants of less than or equal to (\<=) 36 months of age at the time of measurement.
Time frame: Baseline, Week 28
Change From Baseline in Body Mass Index (BMI) Z-score at Week 28
BMI z-score is a measure of relative BMI adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
Time frame: Baseline, Week 28
Change From Baseline in Participants' Stool Consistency at Week 28
Stool consistency was assessed by typical stool form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4 - Like a sausage or snake, smooth and soft, 5 - Soft blobs with clear-cut edges, 6 - Fluffy pieces with ragged edges, a mushy stool, 7 - Watery, no solid pieces, entirely liquid.
Time frame: Baseline, Week 28
Change From Baseline in Hours Per Day of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24
The mean duration of the PN/IV infusions in hours, on the days when PN/IV was administered was reported.
Time frame: Baseline, Week 24
Change From Baseline in Days Per Week of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24
The number of days per week of PN/IV infusions were reported.
Time frame: Baseline, Week 24
Study was conducted at 27 study centers in the United States, Belgium, Canada, the United Kingdom, Finland, Germany and Italy between 03 June 2016 (first participant first visit) and 18 August 2017 (last participant last visit).
| Milestone | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Started | 24 | 26 | 9 |
| Completed | 24 | 26 | 9 |
| Not completed | 0 | 0 | 0 |
Reduction in weight-normalized PN/IV volume was performed using both participant diary and investigator prescribed data. Number of participants who achieved at least a 20% reduction in weight-normalized PN/IV volume between the baseline and week 24/EOT visit were reported.
| Participants | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | 13 | 18 | 1 |
| Investigator Prescribed | 13 | 18 | 2 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs that started or worsened on or after the date of first dose for treatment groups and those that started or worsened on or after the baseline visit for standard of care group.
| Participants | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 24 | 25 | 9 |
A participant was considered to have achieved independence from PN/IV support (completely weaned off PN/IV) if the investigator prescribed no PN/IV at EOT and there was no use of PN/IV recorded in the participant diary during the week prior to EOT.
| Participants | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Number of Participants Who Were Completely Weaned Off Parenteral Nutrition Intravenous (PN/IV) Support at Week 24 | 2 | 3 | 0 |
Change in PN/IV volume was reported based on the participant diary and the investigator prescribed data.
| Milliliters per kilogram per day | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | -16.16 ± 10.52 | -23.30 ± 17.50 | -6.03 ± 4.55 |
| Investigator Prescribed | -11.28 ± 15.51 | -22.13 ± 17.92 | -5.84 ± 9.80 |
Change in PN/IV caloric intake was reported based on the participant diary and the investigator prescribed data.
| Kilocalories per kilogram per day | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | -14.92 ± 8.29 | -18.99 ± 14.28 | -0.46 ± 4.95 |
| Investigator Prescribed | -11.76 ± 10.46 | -18.51 ± 13.22 | -0.27 ± 2.73 |
Plasma citrulline level was reported.
| Micromoles per liter | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Change From Baseline in Plasma Citrulline Levels at Week 24 | 7.7 ± 8.50 | 12.0 ± 12.00 | 0.1 ± 7.79 |
Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.
| Milliliter per kilogram per day | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | 7.69 ± 13.46 | 10.96 ± 16.59 | 0.74 ± 5.91 |
| Investigator Prescribed | 7.67 ± 17.77 | 8.17 ± 17.87 | 0.33 ± 0.90 |
Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.
| Kilocalorie per kilogram per day | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | 8.43 ± 14.39 | 12.98 ± 18.93 | 4.22 ± 13.75 |
| Investigator Prescribed | 7.29 ± 15.88 | 11.47 ± 21.13 | 6.66 ± 14.77 |
Change in PN/IV volume was reported.
| Milliliter per kilogram per day | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | 2.63 ± 7.80 | 1.52 ± 12.68 | -2.99 ± 4.94 |
| Investigator Prescribed | 2.13 ± 6.95 | -0.35 ± 5.96 | -0.91 ± 2.18 |
Change in PN/IV caloric intake was reported.
| Kilocalorie per kilogram per day | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | 0.88 ± 2.94 | -0.91 ± 7.14 | -4.21 ± 10.30 |
| Investigator Prescribed | 0.55 ± 3.42 | 0.08 ± 6.13 | -4.34 ± 11.22 |
Change in plasma citrulline level was reported.
| Micromoles per liter | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Change From Week 24 in Plasma Citrulline Levels at Week 28 | -6.0 ± 9.26 | -9.5 ± 10.33 | 1.8 ± 6.48 |
Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.
| Milliliter per kilogram per day | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | -0.68 ± 3.86 | 1.38 ± 8.41 | -0.75 ± 6.78 |
| Investigator Prescribed | 1.67 ± 5.73 | 0.68 ± 6.65 | 0.39 ± 0.57 |
Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.
| Kilocalorie per kilogram per day | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | -1.07 ± 4.36 | -0.14 ± 7.73 | -0.42 ± 6.13 |
| Investigator Prescribed | 1.28 ± 4.30 | -0.11 ± 3.77 | 0.45 ± 0.64 |
Body weight z-score is a measure of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
| Z-score | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Change From Baseline in Body Weight Z-score at Week 28 | -0.12 ± 0.41 | -0.18 ± 0.59 | -0.05 ± 0.37 |
Body height z-score is a measure of relative height adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
| Z-score | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Change From Baseline in Body Height Z-score at Week 28 | 0 ± 0.29 | 0.05 ± 0.45 | 0.16 ± 0.66 |
Head circumference z-score is a measure of relative head circumference adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Head circumference was collected only for participants of less than or equal to (\<=) 36 months of age at the time of measurement.
| Z-score | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Change From Baseline in Head Circumference Z-score at Week 28 | — | — | -0.014 ± NA |
BMI z-score is a measure of relative BMI adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
| Z-score | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) Z-score at Week 28 | -0.13 ± 0.57 | -0.22 ± 0.70 | -0.25 ± 1.42 |
Stool consistency was assessed by typical stool form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4 - Like a sausage or snake, smooth and soft, 5 - Soft blobs with clear-cut edges, 6 - Fluffy pieces with ragged edges, a mushy stool, 7 - Watery, no solid pieces, entirely liquid.
| Score on a scale | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Change From Baseline in Participants' Stool Consistency at Week 28 | -1.3 ± 1.77 | -1.4 ± 1.38 | -3.3 ± 0.35 |
The mean duration of the PN/IV infusions in hours, on the days when PN/IV was administered was reported.
| Hours per day (hour/day) | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | -2.47 ± 2.73 | -3.03 ± 3.84 | -0.21 ± 0.69 |
| Investigator Prescribed | -1.48 ± 3.59 | -1.79 ± 3.52 | 0.11 ± 0.33 |
The number of days per week of PN/IV infusions were reported.
| Days per week (Days/week) | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| Participant Diary | -0.88 ± 1.78 | -1.34 ± 2.24 | 0 ± 0 |
| Investigator Prescribed | -0.79 ± 1.62 | -1.42 ± 2.32 | 0 ± 0 |
Collected over From start of study treatment up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.025 mg/kg/Day Teduglutide | 0/24 (0%) | 15/24 (62.5%) | 24/24 (100%) |
| 0.05 mg/kg/Day Teduglutide | 0/26 (0%) | 20/26 (76.9%) | 23/26 (88.5%) |
| Standard of Care | 0/9 (0%) | 4/9 (44.4%) | 9/9 (100%) |
| Event | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| PyrexiaGeneral disorders | 4/24 | 7/26 | 1/9 |
| DehydrationMetabolism and nutrition disorders | 4/24 | 0/26 | 0/9 |
| Catheter site infectionInfections and infestations | 0/24 | 3/26 | 0/9 |
| Device related infectionInfections and infestations | 1/24 | 3/26 | 0/9 |
| Corona virus infectionInfections and infestations | 0/24 | 1/26 | 1/9 |
| FungaemiaInfections and infestations | 0/24 | 0/26 | 1/9 |
| Otitis media acuteInfections and infestations | 0/24 | 0/26 | 1/9 |
| RoseolaInfections and infestations | 0/24 | 0/26 | 1/9 |
| Urinary tract infectionInfections and infestations | 1/24 | 0/26 | 1/9 |
| Viral infectionInfections and infestations | 0/24 | 2/26 | 1/9 |
| Event | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care |
|---|---|---|---|
| VomitingGastrointestinal disorders | 10/24 | 8/26 | 5/9 |
| Upper respiratory tract infectionInfections and infestations | 5/24 | 6/26 | 4/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/24 | 10/26 | 3/9 |
| DiarrhoeaGastrointestinal disorders | 8/24 | 2/26 | 1/9 |
| PyrexiaGeneral disorders | 5/24 | 6/26 | 3/9 |
| Alanine aminotransferase increasedInvestigations | 7/24 | 2/26 | 0/9 |
| Abdominal painGastrointestinal disorders | 4/24 | 6/26 | 0/9 |
| NasopharyngitisInfections and infestations | 4/24 | 6/26 | 2/9 |
| Catheter site erythemaGeneral disorders | 0/24 | 1/26 | 2/9 |
| Aspartate aminotransferase increasedInvestigations | 5/24 | 0/26 | 0/9 |
Intention-to-treat (ITT) population included all enrolled participants.
| Age, Continuous(Years) | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care | Total |
|---|---|---|---|---|
| Mean | 6.6 ± 3.61 | 6.2 ± 3.67 | 5.7 ± 4.72 | 6.3 ± 3.76 |
| Sex: Female, Male(Participants) | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care | Total |
|---|---|---|---|---|
| Female | 8 | 7 | 3 | 18 |
| Male | 16 | 19 | 6 | 41 |
| Ethnicity (NIH/OMB)(Participants) | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 4 | 14 |
| Not Hispanic or Latino | 16 | 20 | 2 | 38 |
| Unknown or Not Reported | 3 | 1 | 3 | 7 |
| Race/Ethnicity, Customized(Participants) | 0.025 mg/kg/Day Teduglutide | 0.05 mg/kg/Day Teduglutide | Standard of Care | Total |
|---|---|---|---|---|
| Race Customized — White | 16 | 21 | 2 | 39 |
| Race Customized — Black or African American | 3 | 3 | 1 | 7 |
| Race Customized — Asian | 1 | 1 | 1 | 3 |
| Race Customized — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race Customized — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Race Customized — Other | 1 | 0 | 2 | 3 |
| Race Customized — Not allowed based on local regulations | 3 | 1 | 3 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2016 to primary completion in Aug 2017, 13 months.
Results were first posted in Oct 2018, 1 year 1 month after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide